EPIK-O/ENGOT-OV61: Alpelisib Plus Olaparib vs Cytotoxic Chemotherapy in High-Grade Serous Ovarian Cancer (Phase III Study)

References

• Sung H , FerlayJ, SiegelRLet al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Reid BM , PermuthJB, SellersTA. Epidemiology of ovarian cancer: a review. Cancer Biol. Med.14(1), 9–32 (2017).
   PubMed Web of Science ®Google Scholar
• Mutch DG , PratJ. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol. Oncol.133(3), 401–404 (2014).
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA , CeccaldiR, ShapiroGIet al. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov.5(11), 1137–1154 (2015).
   PubMed Web of Science ®Google Scholar
• Dion L , CartonI, JaillardSet al. The landscape and therapeutic implications of molecular profiles in epithelial ovarian cancer. J. Clin. Med.9(7), 2239 (2020).
   PubMed Web of Science ®Google Scholar
• Bowtell DD , BöhmS, AhmedAAet al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer.15(11), 668–679 (2015).
   PubMed Web of Science ®Google Scholar
• Lheureux S , GourleyC, VergoteIet al. Epithelial ovarian cancer. Lancet393(10177), 1240–1253 (2019).
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E , HilpertF, WeberBet al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol.32(13), 1302–1308 (2014).
   PubMed Web of Science ®Google Scholar
• Burger RA , BradyMF, BookmanMAet al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med.365(26), 2473–2483 (2011).
   PubMed Web of Science ®Google Scholar
• Perren TJ , SwartAM, PfistererJet al. A phase III trial of bevacizumab in ovarian cancer. N. Engl. J. Med.365(26), 2484–2496 (2011).
   PubMed Web of Science ®Google Scholar
• Banerjee S , MooreKN, ColomboNet al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase III trial. Lancet Oncol.22(12), 1721–1731 (2021).
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I , PautierP, PignataSet al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med.381(25), 2416–2428 (2019).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Martin A , PothuriB, VergoteIet al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med.381(25), 2391–2402 (2019).
   PubMed Web of Science ®Google Scholar
• Jayson GC , KohnEC, KitchenerHCet al. Ovarian cancer. Lancet384(9951), 1376–1388 (2014).
   PubMed Web of Science ®Google Scholar
• Mahmood RD , MorganRD, EdmondsonRJet al. First-line management of advanced high-grade serous ovarian cancer. Curr. Oncol. Rep.22(6), 64 (2020).
   PubMed Web of Science ®Google Scholar
• Milanesio MC , GiordanoS, ValabregaG. Clinical implications of DNA repair defects in high-grade serous ovarian carcinomas. Cancers (Basel)12(5), 1315 (2020).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network . Integrated genomic analyses of ovarian carcinoma. Nature474(7353), 609–615 (2011).
   PubMed Web of Science ®Google Scholar
• Ashworth A , LordCJ. Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?Nat. Rev. Clin. Oncol.15(9), 564–576 (2018).
   PubMed Web of Science ®Google Scholar
• Murai J , HuangSY, DasBBet al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res.72(21), 5588–5599 (2012).
   PubMed Web of Science ®Google Scholar
• Mateo J , LordCJ, SerraVet al. A decade of clinical development of PARP inhibitors in perspective. Ann. Oncol.30(9), 1437–1447 (2019).
   PubMed Web of Science ®Google Scholar
• Lynparza® (olaparib) [Prescribing Information]. AstraZeneca Pharmaceuticals LP, Wilmington, DE. https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/00997c3f-5912-486f-a7db-930b4639cd51/00997c3f-5912-486f-a7db-930b4639cd51_viewable_rendition__v.pdf
   Google Scholar
• Moore K , ColomboN, ScambiaGet al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med.379(26), 2495–2505 (2018).
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I , PautierP, PignataSet al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med.381(25), 2416–2428 (2019).
   PubMed Web of Science ®Google Scholar
• Coleman RL , FlemingGF, BradyMFet al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N. Engl. J. Med.381(25), 2403–2415 (2019).
   PubMed Web of Science ®Google Scholar
• Franzese E , CentonzeS, DianaAet al. PARP inhibitors in ovarian cancer. Cancer Treat. Rev.73, 1–9 (2019).
   PubMed Web of Science ®Google Scholar
• Pautier P , HarterP, PisanoCet al. Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial. J. Clin. Oncol.39(Suppl. 15), Abstract 5514 (2021).
   Web of Science ®Google Scholar
• Wilson MK , Pujade-LauraineE, AokiDet al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann. Oncol.28(4), 727–732 (2017).
   PubMed Web of Science ®Google Scholar
• Alvarez RD , MatulonisUA, HerzogTJet al. Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer. Gynecol. Oncol.141(3), 405–409 (2016).
   PubMed Web of Science ®Google Scholar
• Markman M , MarkmanJ, WebsterKet al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J. Clin. Oncol.22(15), 3120–3125 (2004).
   PubMed Web of Science ®Google Scholar
• van Zyl B , TangD, BowdenNA. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment. Endocr. Relat. Cancer25(5), R303–R318 (2018).
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E , BanerjeeS, PignataS. Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives. J. Clin. Oncol.37(27), 2437–2448 (2019).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology (NCCN guidelines). Ovarian Cancer ( version 1.2022) (2022). www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
   Google Scholar
• Matulonis UA , PensonRT, DomchekSMet al. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Ann. Oncol.27(6), 1013–1019 (2016).
   PubMed Web of Science ®Google Scholar
• Gelmon KA , TischkowitzM, MackayHet al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol.12(9), 852–861 (2011).
   PubMed Web of Science ®Google Scholar
• Sandhu SK , SchelmanWR, WildingGet al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol.14(9), 882–892 (2013).
   PubMed Web of Science ®Google Scholar
• Moore KN , SecordAA, GellerMAet al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol.20(5), 636–648 (2019).
   PubMed Web of Science ®Google Scholar
• Piqray® (alpelisib) [Prescribing Information]. Novartis Pharmaceuticals Corporation, East Hanover, NJ. www.novartis.com/us-en/sites/novartis_us/files/piqray.pdf
   Google Scholar
• André F , CiruelosE, RubovszkyGet al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med.380(20), 1929–1940 (2019).
   PubMed Web of Science ®Google Scholar
• Fritsch C , PfisterE, EbelNet al. Determination of the PI3Kα selective inhibitor alpelisib mechanism of action and efficacy in ER+/ PIK3CA mutant breast cancer preclinical models. Cancer Res.78(Suppl. 13), Abstract 3934 (2018).
   Google Scholar
• Rinne N , ChristieEL, ArdashevaAet al. Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer. Cancer Drug Resist.4(3), 573–595 (2021).
   PubMedGoogle Scholar
• Bendell JC , RodonJ, BurrisHAet al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol.30(3), 282–290 (2012).
   PubMed Web of Science ®Google Scholar
• Liu P , ChengH, RobertsTMet al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov.8(8), 627–644 (2009).
   PubMed Web of Science ®Google Scholar
• Fruman DA , ChiuH, HopkinsBDet al. The PI3K pathway in human disease. Cell170(4), 605–635 (2017).
   PubMed Web of Science ®Google Scholar
• Ibrahim YH , García-GarcíaC, SerraVet al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov.2(11), 1036–1047 (2012).
   PubMed Web of Science ®Google Scholar
• Juvekar A , BurgaLN, HuHet al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov.2(11), 1048–1063 (2012).
   PubMed Web of Science ®Google Scholar
• Juvekar A , HuH, YadegaryniaSet al. Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion. Proc. Natl. Acad. Sci. USA113(30), E4338–E4347 (2016).
   PubMed Web of Science ®Google Scholar
• Lahiguera Á , HyroššováP, FiguerasAet al. Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors. EMBO Mol. Med.12(6), e11217 (2020).
   PubMed Web of Science ®Google Scholar
• Liu JF , PalakurthiS, ZengQet al. Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for preclinical evaluation of novel therapeutics. Clin. Cancer Res.23(5), 1263–1273 (2017).
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA , BarryWT, BirrerMet al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol.20(4), 570–580 (2019).
   PubMed Web of Science ®Google Scholar
• Vanderstichele A , LoverixL, BusschaertPet al. Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician’s choice chemotherapy in relapsed ovarian cancer. Gynecol. Oncol.165(1), 14–22 (2022).
   PubMed Web of Science ®Google Scholar
• Cannistra SA , MatulonisUA, PensonRTet al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol.25(33), 5180–5186 (2007).
   PubMed Web of Science ®Google Scholar